ProCE Banner Activity

CME

Time to Move the Goalposts? Examining Strategies to Advance HBV Management

Video

Hear expert faculty discuss which patients with CHB should be treated—including a call to action for earlier treatment of HBV—and the role of quantitative HBsAg testing in clinical practice.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: December 13, 2023

Expiration: December 12, 2024

Share

Faculty

Ira Jacobson

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Target Audience

This program is intended for physicians, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients with chronic hepatitis B.

Program Learning Goal

The goal of this program is to improve learners’ knowledge and competence regarding key strategies for advancing the management of HBV, including early initiation of therapy and the role of quantitative HBsAg monitoring.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select appropriate candidates for early HBV treatment after weighing drug-related considerations, cost-benefit considerations, and impact on patient outcomes

  • Outline the role of quantitative HBsAg in monitoring patients with CHB, including evaluating disease status and predicting disease progression, treatment response, and functional cure

  • Identify current and future clinical scenarios where quantitative HBsAg monitoring is beneficial to patient management

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor/speaker: AbbVie, Aligos, Eiger, Galapagos, Gilead, GlaxoSmithKline, HEPQuant, Mallinckrodt; researcher: Altimmune, Eiger, Gilead, Janssen, Target RWE.

Primary Author

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Ira M. Jacobson, MD: researcher: Assembly Biosciences, Bristol Myers Squibb, Cymabay, Eiger, Enanta, Genkyotex, Gilead, GlaxoSmithKline, Intercept, Janssen, Lilly, Merck, Mirum, Novo Nordisk; consultant/advisor: Aligos, Altimmune, Arbutus, Arrowhead, Gilead, GlaxoSmithKline, Intercept, Janssen, Merck, Roche, Takeda; data monitoring committee: Altimmune, GlaxoSmithKline, Takeda.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Eiger, Gilead, GlaxoSmithKline; researcher: Gilead.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 13, 2023, through December 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.